MassBio is teaming up with McKinsey & Company on a new annual event that brings together innovative seed/series A start-ups with potential investors and strategic partners to learn and network. This all-day event will be held on April 26 on the heels of MassBio’s State of Possible annual meeting.
Why it matters: Innovation is the middle name of the Massachusetts life sciences cluster and is key to the strength and growth of the biopharma, medtech, and healthtech industries going forward. This summit is designed to be both informative and interactive to an audience of entrepreneurs, funders, and collaborators.
What you’ll hear: Across a series of panel discussions and keynote presentations, experts will cover early-stage investing amid economic uncertainty, lessons learned in scaling early-stage bio/med/healthtech, and how company success will be defined in the future. Attendees will also hear pitches from nearly two dozen featured biotech, medtech, and healthtech companies leaning into innovation.
What they’re saying:
- MassBio President and CEO Kendalle Burlin O’Connell: “Current economic conditions present new opportunities and challenges, and the future growth and continued leadership of Massachusetts as a life sciences hub depends on a full-throated embrace of innovation and new energy. The MassBio Align Summit is putting start-ups and investors in the same room to drop knowledge, enable connections, and keep the Commonwealth on top.”
Get the details:
MassBio Align Summit with insights from McKinsey & Company
The Royal Sonesta Boston Hotel
April 26th, 2023. 9AM – 5PM EST
Register at: massbio.org/alignsummit